Skip to main
CGTX
CGTX logo

Cognition Therapeutics (CGTX) Stock Forecast & Price Target

Cognition Therapeutics (CGTX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cognition Therapeutics has reported a significant advancement in its lead program, Zervimesine, which is now supported by an expanded access program funded by an anonymous benefactor for dementia with Lewy bodies, enhancing its market potential. Additionally, the company has achieved over 50% enrollment in the Phase 2 START study of Zervimesine in early Alzheimer's disease, indicating robust progress in its clinical pursuits. Financially, Cognition maintains a strong operational runway into the second quarter of 2026, with managed R&D and G&A expenses demonstrating effective cost control despite a reduction in cash reserves.

Bears say

Cognition Therapeutics Inc is contending with significant market competition from existing or emerging therapies that may hinder its ability to penetrate the market and influence pricing strategies negatively. Additionally, the company faces potential risks related to inadequate patent protection for its technology and product candidate CT1812, which could limit its competitive advantage on a national and international scale. These factors collectively contribute to a negative outlook for the company's stock, as they may adversely affect its market position and revenue potential.

Cognition Therapeutics (CGTX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cognition Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cognition Therapeutics (CGTX) Forecast

Analysts have given Cognition Therapeutics (CGTX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cognition Therapeutics (CGTX) has a Strong Buy consensus rating as of Nov 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cognition Therapeutics (CGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.